UroGen Pharma Ltd.
Clinical trials sponsored by UroGen Pharma Ltd., explained in plain language.
Develops therapies for urological cancers and diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer gel shows promise for rare urinary tract tumors Results expected Mar 2027 (estimated) 🚀 Make-or-break
-
Bladder cancer patients may avoid surgery with new drug
Disease control OngoingThis study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…
Phase 3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New bladder cancer drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…
Phase 3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC